Miguel Quintela-Fandiño
YOU?
Author Swipe
View article: Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations Open
Management of advanced hormone receptor-positive, HER2-negative breast cancer after progression on endocrine therapy plus CDK4/6 inhibitors is challenging due to mutational heterogeneity. Current therapies yield limited efficacy, achieving…
View article: Table 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Table 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Adverse events grade 2 or higher attributed to palbociclib and binimetinib (>5% of the patients).
View article: Figure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Figure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Efficacy results. A, Kaplan–Meier (KM) curve and (B) swimmer plot displaying PFS time for the efficacy population (N = 23). C, Waterfall plot showing the best overall response for the 16 patients with measurable…
View article: Table S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Table S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Representativeness of Study Participants table
View article: Figure S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Figure S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Figure S1 shows CDK6 and p-ERK positivity in screened samples
View article: Figure 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Figure 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Trial schedule and CONSORT diagram. A, Basic trial schedule. Prescreened patients positive for either p-ERK and/or CDK6 were eligible after experiencing RECIST v1.1 disease progression to their first or second treatment line for adv…
View article: Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Baseline characteristics.
View article: Data from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Data from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Purpose:Advanced, pretreated triple-negative breast cancer (TNBC) has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that cyclin-dependent kinase 6 (CDK6) an…
View article: A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer Open
Purpose: Advanced, pretreated triple-negative breast cancer (TNBC) has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that cyclin-dependent kinase 6 (CDK6) a…
View article: Longitudinal clinical, physiological and molecular profiling of female metastatic cancer patients: protocol and feasibility of a multicenter high-definition oncology study
Longitudinal clinical, physiological and molecular profiling of female metastatic cancer patients: protocol and feasibility of a multicenter high-definition oncology study Open
Despite significant advances in precision oncology, a large proportion of patients receiving genomically matched therapies fail to respond. Emerging evidence highlights that cancer outcomes are influenced by multiple non-genetic factors, i…
View article: Predicting resistance to chemotherapy using chromosomal instability signatures
Predicting resistance to chemotherapy using chromosomal instability signatures Open
Chemotherapies are often given without precision biomarkers, exposing patients to toxic side effects without guaranteed benefit. Here we present chromosomal instability signature biomarkers that identify resistance to platinum-, taxane- an…
View article: Ferroptosis: An emerging strategy for managing epithelial ovarian cancer
Ferroptosis: An emerging strategy for managing epithelial ovarian cancer Open
Ferroptosis is a regulated form of cell death characterised by iron-dependent lipid peroxidation, a process intricately linked to cellular redox homeostasis. This form of cell death is induced by the accumulation of intracellular iron and …
View article: A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples
A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples Open
Epigenetic clocks have been widely used to estimate biological age across various tissues, but their accuracy in breast tissue remains suboptimal. Pan-tissue models such as Horvath’s and Hannum’s clocks, perform poorly in predicting chrono…
View article: The impact of a high fat diet and platelet activation on pre-metastatic niche formation
The impact of a high fat diet and platelet activation on pre-metastatic niche formation Open
There is active crosstalk between tumor cells and the tumor microenvironment during metastatic progression, a process that is significantly affected by obesity, particularly in breast cancer. Here we analyze the impact of a high fat diet (…
View article: A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples
A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples Open
Epigenetic clocks have been widely used to estimate biological age across various tissues, but their accuracy in breast tissue remains suboptimal. Pan-tissue models such as Horvath’s and Hannum’s clocks, perform poorly in predicting chrono…
View article: QUICHE reveals structural definitions of anti-tumor responses in triple negative breast cancer
QUICHE reveals structural definitions of anti-tumor responses in triple negative breast cancer Open
While recent innovations in spatial biology have driven new insights into how tissue organization is altered in disease, interpreting these datasets in a generalized and scalable fashion remains a challenge. Computational workflows for dis…
View article: Correction: Applicability of epigenetic age models to next-generation methylation arrays
Correction: Applicability of epigenetic age models to next-generation methylation arrays Open
View article: Data from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer
Data from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer Open
Purpose:Tumor progression has been linked to stiffening of the extracellular matrix caused by fibrosis. Cancer cells can be mechanically conditioned by stiff extracellular matrix, exhibiting a 1,004-gene signature [mechanical conditioning …
View article: Supplementary Figure S1 from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer
Supplementary Figure S1 from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer Open
EFS in the Luminal A/B tumors subset
View article: Supplementary Figure S2 from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer
Supplementary Figure S2 from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer Open
EFS in the basal-like subset.
View article: Supplementary Table S1 from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer
Supplementary Table S1 from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer Open
Concordance between MeCo and 21-gene recurrence scores
View article: Applicability of epigenetic age models to next-generation methylation arrays
Applicability of epigenetic age models to next-generation methylation arrays Open
View article: Epigenetic age prediction drifts resulting from next-generation methylation arrays
Epigenetic age prediction drifts resulting from next-generation methylation arrays Open
Background Epigenetic clocks based on DNA methylation data are routinely used to obtain surrogate measures of biological age and estimate epigenetic age acceleration rates. These tools are mathematical models that rely on the methylation s…
View article: Applicability of epigenetic age models to next-generation methylation arrays
Applicability of epigenetic age models to next-generation methylation arrays Open
Background Epigenetic clocks based on DNA methylation data are routinely used to obtain surrogate measures of biological age and estimate epigenetic age acceleration rates. These tools are mathematical models that rely on the methylation s…
View article: A Novel Silicon Titanium-Diboride Substrate Supports Growth, Aggregation, Mechanosensing, and Invasiveness of Ovarian Cancer Cells to Assess Therapeutic Response to Targeted Therapy
A Novel Silicon Titanium-Diboride Substrate Supports Growth, Aggregation, Mechanosensing, and Invasiveness of Ovarian Cancer Cells to Assess Therapeutic Response to Targeted Therapy Open
View article: Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation Open
Background HER2, TROP2 and PD-L1 are novel targets in triple-negative breast cancer (TNBC). The combined expression status of these targets, and whether they can define prognostic subgroups, is currently undefined. Methods Immunohistochemi…
View article: miR-203 drives breast cancer cell differentiation
miR-203 drives breast cancer cell differentiation Open
View article: Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement Open
View article: Supplementary Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Supplementary Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors Open
Supplementary Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
View article: Supplementary Figure from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Supplementary Figure from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors Open
Supplementary Figure from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors